Harvoni Tablet, Film Coated
NDC 61958-1801
Product Information
Harvoni (ledipasvir and sofosbuvir) is a NDA-approved product labeled by Gilead Sciences, Inc. This medication is a combination of ledipasvir and sofosbuvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It is supplied as a orange tablet, film coated for oral administration. This product entry covers the primary NDC 61958-1801 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
GSI;7985
Code Structure Chart
Product Details
What is NDC 61958-1801?
What are the uses of this product?
What are Active Ingredients of this product?
- LEDIPASVIR 90 mg/1
- SOFOSBUVIR 400 mg/1 - A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- LEDIPASVIR (UNII: 013TE6E4WV)
- LEDIPASVIR (UNII: 013TE6E4WV) (Active Moiety)
- SOFOSBUVIR (UNII: WJ6CA3ZU8B)
- SOFOSBUVIR (UNII: WJ6CA3ZU8B) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ALCOHOL (UNII: 3K9958V90M)
- COPOVIDONE K25-31 (UNII: D9C330MD8B)
- LACTOSE MONOHYDRATE (UNII: EWQ57Q8I5X)
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- CROSCARMELLOSE SODIUM (UNII: M28OL1HH48)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- WATER (UNII: 059QF0KO0R)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- POLYETHYLENE GLYCOL 3350 (UNII: G2M7P15E5P)
- TALC (UNII: 7SEV7J4R1U)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
- POLYVINYL ALCOHOL, UNSPECIFIED (UNII: 532B59J990)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1591943 - ledipasvir 90 MG / sofosbuvir 400 MG Oral Tablet
- RxCUI: 1591949 - Harvoni 90 MG / 400 MG Oral Tablet
- RxCUI: 1591949 - ledipasvir 90 MG / sofosbuvir 400 MG Oral Tablet [Harvoni]
- RxCUI: 1591949 - Harvoni (ledipasvir 90 MG / sofosbuvir 400 MG) Oral Tablet
- RxCUI: 2203895 - ledipasvir 45 MG / sofosbuvir 200 MG Oral Tablet
Which are the Pharmacologic Classes of this product?
- Breast Cancer Resistance Protein Inhibitors - [MoA] (Mechanism of Action)
- Hepatitis C Virus NS5A Inhibitor - [EPC] (Established Pharmacologic Class)
- Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor - [EPC] (Established Pharmacologic Class)
- P-Glycoprotein Inhibitors - [MoA] (Mechanism of Action)
- RNA Replicase Inhibitors - [MoA] (Mechanism of Action)
* Please review the full disclaimer at the bottom of this page.
Patient Education
Ledipasvir and Sofosbuvir
The combination of ledipasvir and sofosbuvir is used alone or in combination with ribavirin (Copegus, Rebetol, Ribasphere, others) to treat certain types of chronic hepatitis C (an ongoing viral infection that damages the liver) in adults and children 3 years of age and older. Sofosbuvir is in a class of antiviral medications called nucleotide polymerase inhibitors. It works by decreasing the amount of hepatitis C virus (HCV) in the body. Ledipasvir is in a class of antiviral medications called HCV NS5A inhibitors. It works by stopping the virus that causes hepatitis C from spreading inside the body.
[Learn More]
* Please review the full disclaimer at the bottom of this page.